Is Dare Bioscience going out of business?

Dare Bioscience, Inc. (DARE) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Dare Bioscience, Inc. (DARE) scores 13 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 66.84% (YoY)

Five questions, kept separate

Survival - Fragile

12-17 mo of estimated runway from 2026-06-30, based on $12.6M of cash and short-term investments against $10.3M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

136.9% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 66.84% (YoY)
• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): -53.12%
• Return on Assets: -59.90%
• Asset Growth Velocity: 72.35% YoY (Aggressive buildout)
• Revenue per Asset Efficiency: 53.03% QoQ (Strong monetization)
• Revenue growth YoY: 4307.66% (YoY) - Early-Stage Surge (low base)
• FCF margin: -997.01% (Inv. Mode)
• Cash Burn Deceleration: -82.24% QoQ improvement (Worsening)
• Working Capital Efficiency: -2.93x (Tight)
• Price / Sales: 13.8x (see Valuation)

Read from filings through 2026-08-17.

Price as of 2026-09-07.